AbbVie Inc. (ABBV) News
Filter ABBV News Items
ABBV News Results
|Event/Time||Symbol||Company||News Detail||Start||End||Change||POWR Rating|
|Loading, please wait...|
Latest ABBV News From Around the Web
Below are the latest news stories about AbbVie Inc that investors may wish to consider to help them evaluate ABBV as an investment opportunity.
AbbVie (ABBV) announces positive long-term results from two Phase 3 clinical trials, SELECT-COMPARE and SELECT-MONOTHERAPY, evaluating Rinvoq (upadacitinib) in rheumatoid arthritis ((RA)) patients. The data were presented at EULAR.Patients in the first study who received daily doses of 15 mg of upadacitinib with methotrexate continued to experience improved signs and...
(Source: Imgflip) Are you feeling a bit giddy right now? Perhaps even a tad euphoric? No one could blame you if you were, given how red hot the stock market has been over the past few months. S&P 500 & My Phoenix Portfolio's Top Winners Since March 23rd Low (Source:...
Is (ABBV) Outperforming Other Medical Stocks This Year?
Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.
Top Ranked Value Stocks to Buy for June 4th
Similar action in AbbVie with a little flat area forming after following up on small reversal yesterday.
From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.
New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis at 72 and 84 weeks in the SELECT-COMPARE (upadacitinib, 15 mg in combination with methotrexate [MTX]) and SELECT-MONOTHERAPY (upadacitinib, 15 mg and 30 mg) Phase 3 clinical trials, respectively.1,2 The safety profile of upadacitinib (15 mg and 30 mg) monotherapy or upadacitinib (15 mg) in combination with MTX was consistent with that observed in the previously reported integrated Phase 3 safety analysis in rheumatoid arthritis, with no new safety risks detected.1-5
With Wall Street notching a 50-day rally amid signs of the economic slump bottoming out and history hinting further gains, investing in stocks that are poised to gain in the near term seems judicious.
Yuva Biosciences, an anti-aging startup based on technology developed by one of the world leaders in mitochondrial sciences, Dr. Keshav K. Singh, is pleased to announce that Dr. Singh joined the Science of AgingSM faculty, a platform owned and run by Allergan Aesthetics Medicine R&D;.